secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-04-19T23:59:59+00:00
Accession:  0001193125-24-101289
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma raises $40M in oversubscribed PIPE financing at $4.80/share
-----------------------------------------------------------------------------

- Gross proceeds of $40M from sale of 5,749,152 shares at $4.80 and pre-funded warrants for 2,584,239 shares at $4.7999.
- Led by Suvretta Capital, with Adage Capital, Nantahala Capital, and other healthcare-focused funds participating.
- Proceeds to fund BB-301 clinical development (natural history lead-in and Phase 1b/2a treatment study) and general corporate purposes.
- Kishen Mehta, portfolio manager at Suvretta, to be considered for board appointment.
- Closing expected by April 22, 2024; Leerink Partners and Citizens JMP acting as placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/0001193125-24-101289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524101289/d826712d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-101289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer